会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 10. 发明申请
    • Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein
    • 用于抑制血浆激肽释放酶的酰化4-脒基和4-胍基苄胺
    • US20060148901A1
    • 2006-07-06
    • US10540958
    • 2004-01-15
    • Jorg SturzebecherTorsten SteinmetzerAndrea Schweinitz
    • Jorg SturzebecherTorsten SteinmetzerAndrea Schweinitz
    • A61K31/195
    • C07K5/06078A61K31/198A61K31/401A61K31/435A61K47/60C07K5/06034C07K5/0606C07K5/06095
    • The invention relates to the use of acylated 4-amidino- or 4-guanidinobenzylamine in accordance with the general formula I P4-P3-P2-P1  (I), where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural α-amino acid or α-imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted or unsubstituted 4-amidino- or 4-guanidinobenzylamine group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for systemic administration as anticoagulants/-antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.
    • 本发明涉及根据通式I的酰化4-脒基 - 或4-胍基苄胺的用途。在线式描述=“在线配方”中,“”“→P4-P3-P2 -P1(I),<?in-line-formula description =“In-line Formulas”end =“tail”?>其中P4是单取代或多取代或未取代的苄基磺酰基,P3是单取代或多取代或未取代的天然 或D构型中的非天然α-氨基酸或α-亚氨基酸,P2是L构型中的单取代或多取代或未取代的天然或非天然α-氨基酸或α-亚氨基酸,P1是单取代或多取代或多取代的 用于抑制血浆激肽释放酶(PK),因子XIa和因子XIIa的非取代的4-脒基 - 或4-胍基苄胺基团,特别是用于防止合成表面上的凝结活化和作为抗凝血剂/抗血栓形成剂的全身给药,特别是 防止 e在合成表面上的凝结活化以避免血栓栓塞事件。